These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 19507165

  • 1. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
    Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B.
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
    [Abstract] [Full Text] [Related]

  • 2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 3. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 4. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
    Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D.
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):329-33. PubMed ID: 25656910
    [Abstract] [Full Text] [Related]

  • 5. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M.
    Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
    [Abstract] [Full Text] [Related]

  • 6. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.
    Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A.
    Blood Cells Mol Dis; 2013 Aug; 51(2):116-24. PubMed ID: 23683771
    [Abstract] [Full Text] [Related]

  • 7. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
    Hughes DA, Ginsberg L, Baker R, Goodwin S, Milligan A, Richfield L, Mehta AB.
    Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
    [Abstract] [Full Text] [Related]

  • 8. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 9. Goal-oriented therapy with miglustat in Gaucher disease.
    Pastores GM, Giraldo P, Chérin P, Mehta A.
    Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
    [Abstract] [Full Text] [Related]

  • 10. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
    Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernández-Galán MA, Franco R, Gil-Cortes C, Giner V, Ibañez A, Latre P, Loyola I, Luño E, Hernández-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
    [Abstract] [Full Text] [Related]

  • 11. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 12. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
    Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P.
    Atherosclerosis; 2010 Apr 23; 209(2):515-9. PubMed ID: 19959168
    [Abstract] [Full Text] [Related]

  • 13. Substrate reduction therapy.
    Platt FM, Jeyakumar M.
    Acta Paediatr; 2008 Apr 23; 97(457):88-93. PubMed ID: 18339196
    [Abstract] [Full Text] [Related]

  • 14. Gastrointestinal disturbances and their management in miglustat-treated patients.
    Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Pastores GM.
    J Inherit Metab Dis; 2011 Oct 23; 34(5):991-1001. PubMed ID: 21779792
    [Abstract] [Full Text] [Related]

  • 15. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
    Pérez-Poyato MS, Gordo MM, Marfa MP.
    Gene; 2012 Sep 10; 506(1):207-10. PubMed ID: 22750297
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study Group.
    Orphanet J Rare Dis; 2012 Dec 27; 7():102. PubMed ID: 23270487
    [Abstract] [Full Text] [Related]

  • 17. Long-term miglustat therapy in children with Niemann-Pick disease type C.
    Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, Giorgino R, Wraith JE.
    J Child Neurol; 2010 Mar 27; 25(3):300-5. PubMed ID: 19822772
    [Abstract] [Full Text] [Related]

  • 18. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
    Giraldo P, Alfonso P, Atutxa K, Fernández-Galán MA, Barez A, Franco R, Alonso D, Martin A, Latre P, Pocovi M.
    Haematologica; 2009 Dec 27; 94(12):1771-5. PubMed ID: 19608672
    [Abstract] [Full Text] [Related]

  • 19. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 20. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A.
    J Inherit Metab Dis; 2004 Nov 08; 27(6):757-66. PubMed ID: 15505381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.